ArticleCurrent health sciences journal
Genistein: A Preliminary In Vitro Evaluation on IMR-32 Neuroblastoma Cells.
Article in Current health sciences journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Isoflavones as multi-target modulators in glioma and neuroblastoma: a mini-review.Pharmacological reports : PR · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma (NB) is a frequent pathology among children with a serious prognosis. Although there is currently a chemotherapeutic treatment, over the years resistance to existing therapy has developed, necessitating new therapeutic approaches. The current study aimed to evaluate in vitro genistein (GEN) on human neuroblastoma cells-IMR-32, a possible candidate for treating NB. The results indicated that GEN does not affect healthy cells (HaCaT), but has a cytotoxic effect on tumor cells, at concentrations of 50 and 75µM, significantly reducing viability. Moreover, depending on the dose, GEN degraded the cell membrane by releasing LDH and caused changes in the cell shape as well as at the nuclear level similar to apoptosis. The data provide an important perspective on the therapeutic effect of GEN at the NB level, opening the way to new directions in treating this pathology with natural compounds.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.